CH420165A - Process for the preparation of new heterocyclic compounds - Google Patents
Process for the preparation of new heterocyclic compoundsInfo
- Publication number
- CH420165A CH420165A CH224663A CH224663A CH420165A CH 420165 A CH420165 A CH 420165A CH 224663 A CH224663 A CH 224663A CH 224663 A CH224663 A CH 224663A CH 420165 A CH420165 A CH 420165A
- Authority
- CH
- Switzerland
- Prior art keywords
- aza
- methyl
- thioxanthene
- solution
- lower alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 2
- GAAYPTPSHXSMEM-UHFFFAOYSA-N 5h-thiochromeno[2,3-b]pyridine Chemical class C1=CC=C2CC3=CC=CC=C3SC2=N1 GAAYPTPSHXSMEM-UHFFFAOYSA-N 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- -1 alkali metal iodate Chemical class 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 150000004967 organic peroxy acids Chemical class 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- YMEPONLBONEIHQ-UHFFFAOYSA-N 7-chlorothiochromeno[2,3-b]pyridin-5-one Chemical compound C1=CC=C2C(=O)C3=CC(Cl)=CC=C3SC2=N1 YMEPONLBONEIHQ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- IBRSSZOHCGUTHI-UHFFFAOYSA-N 2-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Cl IBRSSZOHCGUTHI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011697 sodium iodate Substances 0.000 description 2
- 235000015281 sodium iodate Nutrition 0.000 description 2
- 229940032753 sodium iodate Drugs 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- MYGXGCCFTPKWIH-UHFFFAOYSA-N 4-chloro-1-methylpiperidine Chemical compound CN1CCC(Cl)CC1 MYGXGCCFTPKWIH-UHFFFAOYSA-N 0.000 description 1
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000004966 inorganic peroxy acids Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Substances SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Verfahren zur Herstellung von neuen heterocyclisehen Verbindungen
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von neuen 4-Aza-thioxanthen-Derivaten der Formel I,
EMI1.1
worin R1 ein Wasserstoffatom oder eine niedere Alkylgruppe, R2 ein Wasserstoff-, ein Halogenaatom oder eine niedere Alkylgruppe und R2 eine niedere Alkylgruppe bedeuten.
Erfindungsgemäss gelangt man zu den neuen Verbindungen der allgemeinen Formel I, indem man 4-Aza-thioxanthen-Derivate Formel II,
EMI1.2
worin R1, R2 und R3 obige Bedeutung besitzen, oxydiert.
In den Ausgangssubstanzen der Formel II kann R1 ein Wasserstoffatom oder einen niederen Alkylrest, wie z. B. den Methyl-, Äthyl-, Propyl- oder den Isopropylrest bedeuten, R2 kann für ein Wasserstoff-, Chlor- oder Bromatom oder für einen niederen Alkylrest, wie beispielsweise für den Methyl-, Äthyl-, Propyl- oder Isopropylrest und R3 für den Methyl-, Äthyl-, Propyl-, Isopropyl- oder für den Butylrest stehen.
Die Oxydation des Schwefelatoms gelingt mit geeigneten Oxydationsmitteln, wie z. B. mit Wasserstoffperoxyd, organischen Persäuren, anorganischen Persäure oder ihren Salzen, z. B. Alkalimetaperjodaten.
Die Ausführung des Verfahrens gestaltet sich beispielsweise in der Weise, dass man die essigsaure Lösung der Ausgangssubstanz, wie z. B. 9-[1-Methyl-piperidyliden-(4)]-4-aza-thioxanthen, (ein Mol) mit einem Mol einer verdünnten wässerigen Natriummetaperjodatlösung während 3 bis 5 Stunden bei Raumtemperatur versetzt. Zur Vervollständigung der Reaktion lässt man das Gemisch noch 4 bis 5 Tage bei Raumtemperatur stehen. Nach Entfernen von ausgefallenem Natriumjodat und nach Alkalischmachen mit Ammoniak oder einem Alkalihydroxyd wird das Endprodukt mit einem indifferenten organischen Lösungsmittel, vorzugsweise mit Methylenchlorid, extrahiert, nach bekannten Methoden daraus isoliert und gereinigt.
Anstatt mit einer wässerigen Natriummetaperjodatlösung kann die Oxydation auch mit organischen Persäuren, z. B. mit Perbenzoesäure oder mit Wasserstoffperoxyd bei Raum- oder leicht erhöhter Tem peratur ausgeführt werden, wobei jeweils ein Mol des Oxydationsmittels verwendet wird.
Die erfindungsgemäss hergestellten neuen 4-Azathioxanthen-Derivate der Formel I sind basische, bei Raumtemperatur kristallisierte Verbindungen, die mit organischen und anorganischen Säuren beständige, bei Raumtemperatur kristallisierte Salze bilden.
Solche Salze sind beispielsweise die Hydrochloride, Hydrobromide, Sulfate, Fumarate, Maleinate, Malate, Acetate, Tartrate.
Die erfindungsgemäss hergestellten neuen 4-Azathioxanthen-Derivate besitzen mannigfaltige therapeutisch verwertbare pharmakodynamische Eigenschaften. So zeichnen sie sich durch ausgeprägte histaminherumende, narkosepotenzierende, adrenolytische, sedative und acetylcholinhemmende Wirkung aus. Die neuen Verbindungen sollen deshalb als Antihistaminika, besonders bei Rhinitis allergica, Asthma bronchiale und bei den verschiedensten allergischen Erkrankungen in der Therapie Verwendung finden.
Als Heilmittel können die Verbindungen bzw. ihre wasserlöslichen, physiologisch verträglichen Säureadditionssalze, allein oder in entsprechenden Arzneiformen für enterale oder parenterale Verabreichung verwendet werden. Zwecks Herstellung geeigneter Arzneiformen werden die Wirkstoffe anorganischen oder organischen, pharmakologisch indifferenten Hilfsstoffen verarbeitet; man verwendet z. B. für Tabletten und Dragees: Milchzucker, Stärke, Talk, Stearinsäure usw., für Injlaktionspräparate: Wasser, Alkohole, Glycerin, pflanzliche Öle und dergleichen, für Suppositorien: Natürliche oder gehärtete Öle und Wachse und andere mehr.
Ausserdem können die Zubereitungen geeignete Konservierungs-, Stabilisierungsmittel, Netzmittel, Lösungsvermittler, Süss- und Farbstoffe, Aromantien usw. enthalten.
Ausgangssubstanzen, worin R1 Wasserstoff und R2 Halogen bedeuten, können aus 7-Halogen4-aza-thioxanthonen und 1-ALkyl-4-halogen-piperi- dinen durch Grignard-Reaktion, Hydrolyse und anschliessende Wasserabspaltung hergestellt werden. Die 7-Halogen-4-aza-thioxanthone ihrerseits erhält man durch Kondensation von 2-Chlor-nicotinsäure mit einem 4-Halogen-thiophenol und anschliessende Cyclisierung des entstandenen Carboxy-piperidyl- (2) -phenylsulfid-Derivats mit Polyphosphorsäure.
In den nachfolgenden Beispielen, welche die Ausführung des Verfahrens erläutern, die Erfindung aber in keiner Weise einschränken sollen, erfolgen alle Temperaturangaben in Celsiusgraden und sind unkorrigiert.
Beispiel 1 9-[1 -Methyl-piperidyliden-(4)]-
4-aza-thioxanthen-1 O-oxyd
Zu einer Lösung von 8,82 g 9-[1-Methyl-piper- idyliden - (4)] - 4 - aza-thioxanthen (Smp. 166-1670 aus Aceton) in 30 cm3 Wasser und 2,0 cm8 Eisessig lässt man während 4 Std. unter gutem Rühren die Lösung von 7,06 g Natriummetaperjodat in 80 cm3 Wasser zutropfen und rührt das Reaktionsgemisch anschliessend noch 5 Tage bei Raumtemperatur. Ausgeschiedenes Natriumjodat wird abfiltriert, das Filtrat mit Kalilauge alkalisch gestellt und mehrmals mit Methylenchlorid extrahiert. Nach Trocknen der vereinigten Extrakte über Magnesiumsulfat und Abdampfen des Lösungsmittels wird der Rückstand dreimal aus Äthanol umkristallisiert.
Das 9-[1-Methyl-piperidyliden- (4)]-4-aza-thioxanthen-10-oxyd schmilzt bei 226-2280 (Zers.).
Beispiel 2 7-Chlor-9-[1 methyl-piperidyliden-(4)]-
4-aza-thioxanthen-1 O-oxyd
Die Suspension von 3,29 g 7-Chlor-9-[1-me thyl-piperidyliden - (4)] - 4 -aza-thioxanthen (Smp. 150 bis 1520) in 50 cm3 Wasser¯ und 0,68 cm3 Eisessig wird unter gutem Rühren bei Raumtemperatur innerhalb von 80 Min. mit der Lösung von 2,46 g Natriummetaperjodat in 20 cm3 Wasser versetzt und die allmählich entstandene klare Lösung anschliessend noch 24 Std. bei Raumtemperatur weitergerührt. Nach Alkalischmachen mit 7,5 cm3 2n Natronlauge extrahiert man das ausgefallene Rohprodukt mit Methylenchlorid und trocknet den Extrakt über Natriumsulfat.
Nach Abdampfen des Lösungsmittels wird der Rückstand in Aceton aufgenommen und das Aceton durch Verdampfen entfernt. Das 7-Chlor-9-[1-methyl-piperidyliden-(4)]- 4-aza-thioxanthen-l0-oxyd wird zweimal aus Äthanol umkristallisiert. Smp. 225-2260 (Zers.).
Das als Ausgangssubstanz verwendet 7-Chlor 9 - [1 - methyl-piperidyliden - (4)] -4- aza-thioxanthen wird wie folgt hergestellt:
7-Chlor-4-aza-thioxanthon
78 g (0,5 Mol) 2-Chlor-nicotinsäure und 145 g (1 Mol) p-Chlorthiophenol werden 3 Stunden auf
1700 erwärmt. Dann kühlt man ab und verrührt das kristalline Reaktionsprodukt mit 500 cm3 Äther und 1000 cm3 gesättigter Natriumhydrogencarbonatlösung, bis alles gelöst ist. Die Ätherschicht wird dann abgetrennt und nochmals mit Natriumhydrogencarbonatlösung ausgeschüttelt. Die vereinigten wässerigen Extrakte werden mit Essigsäure auf ein pH von 5 gestellt.
Die ausgefallene Substanz, das 3-Carboxypyridyl-(2)-p-chlorphenylsulfid, wird abfiltriert, getrocknet und aus Methanol umkristallisiert. Smp. 216 bis 2170.
35 g 3 - Carboxy - pyridyl-(2)-p-chlorphenylsulfid werden mit 350 g Polyphosphorsäure 1 Std. auf
1500, dann 2 Std. auf 1800 erhitzt. Nach Abkühlen auf etwa 1000 lässt man das Reaktionsgemisch unter gutem Rühren in 1500 cm3 Wasser einfliessen. Die ausgefallene Substanz wird abfiltriert, dann mit
200 cm3 10pro. Natronlauge 10 Min. gerührt, wie der abfiltriert, gut mit Wasser gewaschen, getrocknet und aus Eis essig umkristallisiert.
Das 7- Chlor -4- aza - thioxanthon schmilzt bei 194-195 .
7-Chlor-9-[1 -methyl-piperidyl-(4)]-
4-aza-thioxanthydrol
2,43 g mit Jod aktivierte Magnesiumspäne werden mit 10 cm3 Tetrahydrofuran überschichtet und mit 0,3 cm8 Äthylenbromid versetzt, wodurch die Reaktion in Gang gebracht wird. Sodann lässt man die Lösung von 14,7 g (0,11 Mol) l-Methyl-4-chlor- piperidin in 25 cm3 abs. Tetrahydrofuran in solcher Geschwindigkeit zutropfen, dass die Reaktionsmischung ständig siedet. Anschliessend erhitzt man noch 1-2 Std., bis das Magnesium zum grössten Teil gelöst ist, kühlt ab und gibt bei 20-25 portionenweise 12,4 g (0,05 Mol) 7-Chlor-4-aza-thioxanthon zu. Nach 20 Min. Rühren bei Raumtemperatur giesst man das Reaktionsgemisch auf 300 cm3 10pro.
Ammoniumchloridlösung und schüttelt mit Methylenchlorid aus. Nach Trocknen über Magnesiumsulfat und Verdampfen des Lösungsmittels wird der Rüclc- stand aus Aceton umkristallisiert. Smp. 225-226 .
7-Chlor-9- [1 -methyl-piperidyliden-(4)] -
4-aza-thioxanthen
10 g 7 - Chlor -9- [1-methyl-piperidyl-(4)]-4-aza- thioxanthydrol werden mit einer Mischung von 25 cm3 Wasser und 75 cm3 konz. Schwefelsäure 20 Min. auf 1400 erhitzt. Dann giesst man auf 500com3 Eiswasser, stellt die Lösung mit 50proz.
Natronlauge alkalisch und schüttelt mit Methylenchlorid aus. Nach Trocknen über Kaliumcarbonat und Abdampfen des Lösungsmittels wird der Rückstand aus Aceton umkristallisiert. Smp. 150-152 .
Beispiel 3 3-Methyl-9-[1 -methyl-piperidyliden-(4)]
4-aza-thioxanthen-1 O-oxyd
Die Lösung von 4,58 g 3-Methyl-9-[1-methylpiperidyliden-(4)]-4-aza-thioxanthen (Smp. 195 bis 1960) in 75 cm3 Wasser und 1,02 cm3 Eisessig wird unter gutem Rühren bei Raumtemperatur innerhalb von 70 Min. mit der Lösung von 3,70 g Natriummetaperjodat in 35 cm3 Wasser versetzt. Nach 20stündigem Rühren bei Raumtemperatur stellt man das Reaktionsgemisch mit konz. Ammoniumhydroxydlösung alkalisch und extrahiert mehrmals mit Methylenchlorid. Nach Trocknen der vereinigten Extrakte über Natriumsulfat und Abdampfen des Lösungsmittels wird der Rückstand aus Aceton umkristallisiert.
Das 3 -Methyl-9-[ 1 -methyl-piperidyli- den- (4)]-4-aza-thioxanthen-10-oxyd schmilzt bei 195-196 (Zers.).
Process for the preparation of new heterocyclic compounds
The present invention relates to a process for the preparation of new 4-aza-thioxanthene derivatives of the formula I,
EMI1.1
wherein R1 is a hydrogen atom or a lower alkyl group, R2 is a hydrogen atom, a halogen atom or a lower alkyl group and R2 is a lower alkyl group.
According to the invention, the new compounds of general formula I are obtained by adding 4-aza-thioxanthene derivatives of formula II,
EMI1.2
where R1, R2 and R3 have the above meanings, oxidized.
In the starting substances of the formula II, R1 can be a hydrogen atom or a lower alkyl radical, such as. B. denote the methyl, ethyl, propyl or isopropyl radical, R2 can represent a hydrogen, chlorine or bromine atom or for a lower alkyl radical, such as for the methyl, ethyl, propyl or isopropyl radical and R3 for the methyl, ethyl, propyl, isopropyl or butyl radical.
The sulfur atom can be oxidized with suitable oxidizing agents, such as. B. with hydrogen peroxide, organic peracids, inorganic peracids or their salts, e.g. B. Alkali Metaperiodata.
The execution of the method is designed, for example, in such a way that the acetic acid solution of the starting substance, such as. B. 9- [1-methyl-piperidylidene- (4)] -4-aza-thioxanthene, (one mole) mixed with one mole of a dilute aqueous sodium metaperiodate solution for 3 to 5 hours at room temperature. To complete the reaction, the mixture is left to stand at room temperature for a further 4 to 5 days. After removing the precipitated sodium iodate and making it alkaline with ammonia or an alkali metal hydroxide, the end product is extracted with an inert organic solvent, preferably with methylene chloride, isolated therefrom by known methods and purified.
Instead of using an aqueous sodium metaperiodate solution, the oxidation can also be carried out with organic peracids, e.g. B. with perbenzoic acid or with hydrogen peroxide at room temperature or slightly elevated Tem temperature, one mole of the oxidizing agent is used.
The new 4-azathioxanthene derivatives of the formula I prepared according to the invention are basic compounds which crystallize at room temperature and which form stable salts which crystallize at room temperature with organic and inorganic acids.
Such salts are, for example, the hydrochloride, hydrobromide, sulfate, fumarate, maleate, malate, acetate, tartrate.
The new 4-azathioxanthene derivatives prepared according to the invention have a wide variety of therapeutically utilizable pharmacodynamic properties. They are characterized by a pronounced histamine-surrounding, narcosis-potentiating, adrenolytic, sedative and acetylcholine-inhibiting effect. The new compounds are therefore intended to be used as antihistamines in therapy, especially in allergic rhinitis, bronchial asthma and in a wide variety of allergic diseases.
The compounds or their water-soluble, physiologically tolerable acid addition salts, alone or in appropriate medicinal forms for enteral or parenteral administration, can be used as medicaments. In order to produce suitable pharmaceutical forms, the active ingredients are processed as inorganic or organic, pharmacologically indifferent auxiliary substances; one uses z. B. for tablets and dragees: lactose, starch, talc, stearic acid etc., for injection preparations: water, alcohols, glycerine, vegetable oils and the like, for suppositories: natural or hardened oils and waxes and others.
In addition, the preparations can contain suitable preservatives, stabilizers, wetting agents, solubilizers, sweeteners, colorants, flavorings, etc.
Starting substances in which R1 is hydrogen and R2 is halogen can be prepared from 7-halo-4-aza-thioxanthones and 1-alkyl-4-halo-piperidines by a Grignard reaction, hydrolysis and subsequent elimination of water. The 7-halo-4-aza-thioxanthones, in turn, are obtained by condensation of 2-chloro-nicotinic acid with a 4-halo-thiophenol and subsequent cyclization of the resulting carboxy-piperidyl- (2) -phenylsulfide derivative with polyphosphoric acid.
In the following examples, which illustrate the implementation of the process but are not intended to restrict the invention in any way, all temperatures are given in degrees Celsius and are uncorrected.
Example 1 9- [1 -Methyl-piperidylidene- (4)] -
4-aza-thioxanthene-1 O-oxide
It is added to a solution of 8.82 g of 9- [1-methyl-piperidylidene- (4)] -4-aza-thioxanthene (melting point 166-1670 from acetone) in 30 cm3 of water and 2.0 cm8 of glacial acetic acid The solution of 7.06 g of sodium metaperiodate in 80 cm3 of water is added dropwise over a period of 4 hours with thorough stirring and the reaction mixture is then stirred for a further 5 days at room temperature. The precipitated sodium iodate is filtered off, the filtrate is made alkaline with potassium hydroxide solution and extracted several times with methylene chloride. After the combined extracts have been dried over magnesium sulfate and the solvent has been evaporated off, the residue is recrystallized three times from ethanol.
The 9- [1-methyl-piperidylidene- (4)] -4-aza-thioxanthene-10-oxide melts at 226-2280 (dec.).
Example 2 7-chloro-9- [1 methyl-piperidylidene- (4)] -
4-aza-thioxanthene-1 O-oxide
The suspension of 3.29 g of 7-chloro-9- [1-methyl-piperidylidene- (4)] -4-aza-thioxanthene (melting point 150 to 1520) in 50 cm3 of water and 0.68 cm3 of glacial acetic acid becomes The solution of 2.46 g of sodium metaperiodate in 20 cm3 of water was added with thorough stirring at room temperature over the course of 80 minutes and the clear solution which had gradually formed was then stirred for a further 24 hours at room temperature. After making it alkaline with 7.5 cm3 of 2N sodium hydroxide solution, the precipitated crude product is extracted with methylene chloride and the extract is dried over sodium sulfate.
After evaporation of the solvent, the residue is taken up in acetone and the acetone is removed by evaporation. The 7-chloro-9- [1-methyl-piperidylidene- (4)] -4-aza-thioxanthene-10 oxide is recrystallized twice from ethanol. M.p. 225-2260 (dec.).
The 7-chloro 9 - [1 - methyl-piperidylidene - (4)] -4-aza-thioxanthene used as the starting substance is prepared as follows:
7-chloro-4-aza-thioxanthone
78 g (0.5 mol) of 2-chloro-nicotinic acid and 145 g (1 mol) of p-chlorothiophenol are on for 3 hours
Heated in 1700. It is then cooled and the crystalline reaction product is stirred with 500 cm3 of ether and 1000 cm3 of saturated sodium hydrogen carbonate solution until everything has dissolved. The ether layer is then separated off and extracted again with sodium hydrogen carbonate solution. The combined aqueous extracts are adjusted to pH 5 with acetic acid.
The precipitated substance, 3-carboxypyridyl- (2) -p-chlorophenyl sulfide, is filtered off, dried and recrystallized from methanol. M.p. 216 to 2170.
35 g of 3-carboxy-pyridyl- (2) -p-chlorophenyl sulfide are mixed with 350 g of polyphosphoric acid for 1 hour
1500, then heated to 1800 for 2 hours. After cooling to about 1000, the reaction mixture is allowed to flow into 1500 cm3 of water with thorough stirring. The precipitated substance is filtered off, then with
200 cm3 10 per. Sodium hydroxide solution stirred for 10 minutes, like that filtered off, washed well with water, dried and recrystallized from ice-cream.
The 7-chloro -4-aza-thioxanthone melts at 194-195.
7-chloro-9- [1 -methyl-piperidyl- (4)] -
4-aza-thioxanthydrol
2.43 g of magnesium shavings activated with iodine are covered with a layer of 10 cm3 of tetrahydrofuran and 0.3 cm8 of ethylene bromide is added to start the reaction. The solution of 14.7 g (0.11 mol) of 1-methyl-4-chloropiperidine in 25 cm3 of abs. Add tetrahydrofuran dropwise at such a rate that the reaction mixture boils continuously. The mixture is then heated for another 1-2 hours until most of the magnesium has dissolved, cooled and 12.4 g (0.05 mol) of 7-chloro-4-aza-thioxanthone are added in portions at 20-25 times. After stirring for 20 minutes at room temperature, the reaction mixture is poured into 300 cm3 of 10pro.
Ammonium chloride solution and extracted with methylene chloride. After drying over magnesium sulfate and evaporation of the solvent, the residue is recrystallized from acetone. M.p. 225-226.
7-chloro-9- [1-methyl-piperidylidene- (4)] -
4-aza-thioxanthene
10 g of 7-chloro -9- [1-methyl-piperidyl- (4)] - 4-aza- thioxanthydrol are concentrated with a mixture of 25 cm3 of water and 75 cm3. Sulfuric acid heated to 1400 for 20 min. Then you pour 500 cc of ice water, the solution is 50 percent.
Sodium hydroxide solution is alkaline and extracted with methylene chloride. After drying over potassium carbonate and evaporation of the solvent, the residue is recrystallized from acetone. M.p. 150-152.
Example 3 3-Methyl-9- [1 -methyl-piperidylidene- (4)]
4-aza-thioxanthene-1 O-oxide
The solution of 4.58 g of 3-methyl-9- [1-methylpiperidylidene- (4)] -4-aza-thioxanthene (melting point 195 to 1960) in 75 cm3 of water and 1.02 cm3 of glacial acetic acid is added with thorough stirring A solution of 3.70 g of sodium metaperiodate in 35 cm3 of water was added to room temperature within 70 minutes. After stirring for 20 hours at room temperature, the reaction mixture is made with conc. Ammonium hydroxide solution is alkaline and extracted several times with methylene chloride. After the combined extracts have been dried over sodium sulfate and the solvent has been evaporated off, the residue is recrystallized from acetone.
The 3-methyl-9- [1-methyl-piperidylidene- (4)] -4-aza-thioxanthene-10-oxide melts at 195-196 (dec.).
Claims (1)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH224663A CH420165A (en) | 1963-02-22 | 1963-02-22 | Process for the preparation of new heterocyclic compounds |
| GB4109/64A GB1046543A (en) | 1963-02-22 | 1964-01-31 | Improvements in or relating to azathiaxanthene derivatives |
| ES296634A ES296634A1 (en) | 1963-02-22 | 1964-02-20 | Procedure for the production of new heterocyclic compounds (Machine-translation by Google Translate, not legally binding) |
| AT143264A AT240376B (en) | 1963-02-22 | 1964-02-20 | Process for the preparation of new 4-aza-thioxanthene derivatives |
| FR964537A FR1392047A (en) | 1963-02-22 | 1964-02-20 | New compounds derived from 4-aza-thiaxanthene and their preparation |
| BE644121A BE644121A (en) | 1963-02-22 | 1964-02-20 | |
| DK86664A DK103831C (en) | 1963-02-22 | 1964-02-21 | Process for the preparation of 4-azathioxanthene derivatives or acid addition salts thereof. |
| FR975012A FR3403M (en) | 1963-02-22 | 1964-05-19 | Drug based on new derivatives of 4-aza-thiaxanthene. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH224663A CH420165A (en) | 1963-02-22 | 1963-02-22 | Process for the preparation of new heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH420165A true CH420165A (en) | 1966-09-15 |
Family
ID=4229268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH224663A CH420165A (en) | 1963-02-22 | 1963-02-22 | Process for the preparation of new heterocyclic compounds |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH420165A (en) |
-
1963
- 1963-02-22 CH CH224663A patent/CH420165A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH651563A5 (en) | HYDROXYIMINO-OCTAHYDRO-INDOLO (2,3-A) CHINOLIZIN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF. | |
| DE3326164A1 (en) | NEW P-OXIBENZOESAEE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS | |
| CH420165A (en) | Process for the preparation of new heterocyclic compounds | |
| DE1470256A1 (en) | Process for the preparation of new heterocyclic compounds | |
| DE1001261B (en) | Process for the preparation of basic esters of endocyclically substituted almond acids and their salts | |
| DD150060A5 (en) | PROCESS FOR THE PREPARATION OF NEW PHENTHIAZINE DERIVATIVES | |
| DE2854341C2 (en) | ||
| CH420164A (en) | Process for the preparation of new heterocyclic compounds | |
| AT267514B (en) | Process for the preparation of new pyrrolidine derivatives and their salts | |
| AT250381B (en) | Process for the production of new phenothiazines | |
| CH421104A (en) | Process for the preparation of new heterocyclic compounds | |
| AT355033B (en) | METHOD FOR PRODUCING NEW CHINAZOLONE DERIVATIVES AND THEIR SALTS | |
| AT231449B (en) | Process for the preparation of substituted 3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxydes | |
| AT233583B (en) | Process for the preparation of new 1-azathiaxanthene derivatives | |
| AT254835B (en) | Process for the preparation of new sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxydes | |
| AT218519B (en) | Process for the preparation of new pyrazole derivatives | |
| AT346844B (en) | PROCESS FOR PREPARING NEW OXAZOLE DERIVATIVES | |
| CH473138A (en) | Process for the preparation of new 9,10-dihydro-4H-benzo (4,5) cyclohepta (1,2-b) thiophene derivatives | |
| DE1470263A1 (en) | New heterocyclic compounds and processes for their preparation | |
| DE1080114B (en) | Process for the preparation of substituted coumarones | |
| AT256834B (en) | Process for the preparation of new aminoalkyl-substituted 5-membered heterocycles and their salts | |
| AT231425B (en) | Process for the preparation of new basic compounds and their salts | |
| CH433300A (en) | Process for the preparation of new heterocyclic compounds | |
| AT235291B (en) | Process for the preparation of new benz [b] cycloalkan-1-ones | |
| AT248434B (en) | Process for the preparation of new pyridine derivatives |